6/9
05:31 am
avbp
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M [Seeking Alpha]
Low
Report
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M [Seeking Alpha]
6/6
08:02 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
6/5
10:26 pm
avbp
Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products [Yahoo! Finance]
Low
Report
Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products [Yahoo! Finance]
6/5
07:08 am
avbp
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab [Yahoo! Finance]
Low
Report
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab [Yahoo! Finance]
6/5
07:00 am
avbp
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Low
Report
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
5/16
04:05 pm
avbp
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
Low
Report
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
5/16
05:14 am
avbp
InnoCare Pharma concludes subject enrolment Phase II psoriasis trial [Yahoo! Finance]
Medium
Report
InnoCare Pharma concludes subject enrolment Phase II psoriasis trial [Yahoo! Finance]
5/9
08:17 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
5/8
08:21 am
avbp
ArriVent BioPharma Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/8
08:00 am
avbp
ArriVent BioPharma Reports First Quarter 2024 Financial Results
Low
Report
ArriVent BioPharma Reports First Quarter 2024 Financial Results
4/30
07:15 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.
4/22
04:05 pm
avbp
ArriVent Appoints Kristine Peterson to its Board of Directors
Low
Report
ArriVent Appoints Kristine Peterson to its Board of Directors
3/28
08:39 pm
avbp
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib [Yahoo! Finance]
Low
Report
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib [Yahoo! Finance]
3/28
08:30 pm
avbp
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
Low
Report
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
3/28
04:19 pm
avbp
ArriVent BioPharma Reports Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/28
04:05 pm
avbp
ArriVent BioPharma Reports Full Year 2023 Financial Results
Low
Report
ArriVent BioPharma Reports Full Year 2023 Financial Results